2013美國(guó)臨床內(nèi)分泌醫(yī)師協(xié)會(huì)糖尿病專家共識(shí)
《2013美國(guó)臨床內(nèi)分泌醫(yī)師協(xié)會(huì)糖尿病專家共識(shí)》內(nèi)容簡(jiǎn)介：
This document is organized into discrete sections thataddress the following topics: obesity, prediabetes, manage-ment of hyperglycemia through lifestyle modifications,pharmacotherapy and insulin, management of hyperten-sion, management of hyperlipidemia, and other risk-reduc-tion strategies.
《2013美國(guó)臨床內(nèi)分泌醫(yī)師協(xié)會(huì)糖尿病專家共識(shí)》內(nèi)容預(yù)覽：
Prediabetes reflects failing pancreatic compensationto an underlying state of insulin resistance, most com-monly caused by excess body weight or obesity. Currentcriteria for the diagnosis of prediabetes include impairedglucose tolerance, impaired fasting glucose, or metabolicsyndrome. （See Comprehensive Diabetes ManagementAlgorithm-Prediabetes Algorithm）。 Any one of these fac-tors is associated with a 5-fold increase in future T2DMrisk （12）。
The primary goal of prediabetes management isweight loss. Whether achieved through TLC, pharmaco-therapy, surgery, or some combination thereof, weight lossreduces insulin resistance and can effectively prevent pro-gression to diabetes as well as improve lipids and bloodpressure. However, weight loss may not directly addressthe pathogenesis of declining beta-cell function. Whenindicated, bariatric surgery can also be highly effective inpreventing progression to diabetes （12）。
點(diǎn)擊下載***：《2013美國(guó)臨床內(nèi)分泌醫(yī)師協(xié)會(huì)糖尿病專家共識(shí)》
本站所注明來(lái)源為"愛愛醫(yī)"的文章，版權(quán)歸作者與本站共同所有，非經(jīng)授權(quán)不得轉(zhuǎn)載。
本站所有轉(zhuǎn)載文章系出于傳遞更多信息之目的，且明確注明來(lái)源和作者，不希望被轉(zhuǎn)載的媒體或個(gè)人可與我們
聯(lián)系z(mì)lzs@120.net，我們將立即進(jìn)行刪除處理
